Market Access Questions linger as England’s Innovative Medicines Fund kick... In part one of this two-article series on the latest on England’s Innovative Medic
Market Access Time is motor neurons – the importance of newborn screening ... Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1 gene that results in the progressive and irreversible loss of motor neuro
Market Access Is it time to rethink electronic prescribing in the US? It is a fact of life that most – if not all – patients will require some form of prescription medication during their lifetime.
Partner Content Partner Content Data-driven policy and market access firm Avalere joins Fish... June 7, 2022, Washington DC – Fishawack Health (FH) announ
Market Access Combination pricing: access to the future of oncology treatm... Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the world.
Market Access Closing the digital expectation gap in pharma Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to refer to what he does as “innovation”.
News Beren's Niemann-Pick drug Lembaz cleared by FDA The FDA has approved Beren's Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.